Please assess the completion status of the following clinical trial:

Trial Title: A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese elderly and young males and females (of non-childbearing potential)~* Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 40 kg and no more than 100 kg~Exclusion Criteria:~* Psychiatric disease/condition, GI, renal, hepatic, cardiovascular, psychiatric, or retinal diseases or disorders~* Use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs.~* Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other nicotine products.~* Neurological disease, including seizures, recent memory impairment, or clinically significant head injury.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- AZD3293 (Type: EXPERIMENTAL): AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given (2 subjects in each cohort)

Based on this trial design, predict the completion outcome and termination type (if applicable).